VHH in
Cell Therapies
Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.
VHH can also be easily multimerised to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity. Away from the ectodomain, their small size also permits packaging of more sophisticated intracellular signalling domains, supporting the next generation of cell therapies.
![VHH-CAR-T-icon](https://isogenica.com/wp-content/uploads/2022/09/VHH-CAR-T-icon.png)
Advantages of
VHH in Cell Therapy
![VHH-CART-T-Figure-1](https://isogenica.com/wp-content/uploads/2022/09/VHH-CART-T-Figure-1.png)
Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.
![VHH-CART-T-Table-1](https://isogenica.com/wp-content/uploads/2022/09/VHH-CART-T-Table-1.jpg)
References:
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811
![Poster screenshot](https://isogenica.com/wp-content/uploads/2023/07/Poster-screenshot.png)
Isogenica’s
VHH in CAR-T Resources
On the Origin of VHHs: Student serendipity and coincidental camels
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
Review: Immunogenicity Risk Profile of Nanobodies
Ackaert et al review the immunogenicity risk profile of two VHHs from Phase II clinical trials, examining pre-existing ADAs and comparing to 3 months post-administration.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.